58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Autor:	F. Marmé, C. Hanusch, J. Furlanetto, P. Morris, T. Link, C. Denkert, P.A. Fasching, C. Jackisch, S. Antolín, C. Solbach, P. Aftimos, J. Huober, M. Untch, M. Balic, M. Reinisch, J-U. Blohmer, A. Gonçalves, J. Rey, T. Büchele, S. Loibl
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S148-S149
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4b53e23464ebf841a46c7f7015893a64 https://doi.org/10.1016/j.annonc.2022.03.074 Zobrazit plný text záznamu